New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- Combo Biologics in RA? Be Cautious on December 27, 2018 at 3:57 pm
Patients with rheumatoid arthritis (RA) who were treated with a combination of two biologic agents had an increased risk for adverse events, a meta-analysis showed. In a pooled analysis that included ... […]
- Have Insiders Been Buying ADMA Biologics, Inc. (NASDAQ:ADMA) Shares This Year? on December 26, 2018 at 10:21 am
We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders ... […]
- The global biologics market is estimated to reach $250bn in 2023 on December 24, 2018 at 5:03 am
NEW YORK, Dec. 24, 2018 /PRNewswire/ -- Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Fact... […]
- Here is What Hedge Funds Think About ADMA Biologics Inc (ADMA) on December 23, 2018 at 4:48 am
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze ... […]
- Review of Biologics in Children With Severe Asthma on December 21, 2018 at 7:19 am
Medications certainly play a role in asthma management. Several have been introduced in recent years, including tiotropium, a long-acting anticholinergic; mepolizumab and reslizumab, anti-interleukin ... […]
- Integrase Inhibitor Pipeline Insight, 2018 Report Featuring Gilead Sciences, ViiV Healthcare, TaiMed Biologics & GSK - ResearchAndMarkets.com on December 21, 2018 at 6:26 am
DUBLIN--(BUSINESS WIRE)--The "Integrase Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. Integrase Inhibitor - Pipeline Insight, 2018' report ... […]
- Global Biologics Market Forecasts From 2018 to 2023 - ResearchAndMarkets.com on December 21, 2018 at 1:24 am
DUBLIN--(BUSINESS WIRE)--The "Global Biologics Market - Forecasts From 2018 to 2023" report has been added to ResearchAndMarkets.com's offering. The global biologics market is expected to reach US ... […]
- Here's Why ADMA Biologics Is Getting Hammered Today on December 20, 2018 at 2:20 pm
ADMA Biologics collects and sells plasma and plasma-derived products -- albeit poorly. The company hasn't earned a gross profit since 2017, and operations lost a frightening $44 million during the fir... […]
- The biologics outsourcing global market is expected to grow at double digit CAGR to reach $87.6 billion by 2027 on December 20, 2018 at 1:34 pm
NEW YORK, Dec. 20, 2018 /PRNewswire/ -- The biologics outsourcing global market is expected to grow at double digit CAGR to reach $87.6 billion by 2027. Read the full report: https://www.reportlinker. ... […]
- Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial on December 20, 2018 at 12:14 pm
Merck MRK, -0.38% known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics Licens... […]
via Bing News